HAS-BLED Score Calculator

How to Use This Calculator

1. Select each HAS-BLED risk factor from the dropdowns.
2. Your score, risk tier, and estimated major bleeding rate update instantly.
3. Use the Modifiable Risk Factors tab to identify what you can address.
4. Use the Net Clinical Benefit tab with CHA₂DS₂-VASc to weigh stroke vs bleed risk.

Formula

Example

Frequently Asked Questions

• What is the HAS-BLED score and how is it calculated? ▼
  HAS-BLED is a clinical scoring system developed to estimate the risk of major bleeding in patients with atrial fibrillation who are being considered for anticoagulation. It was derived and validated by Pisters et al. in the Euro Heart Survey AFib cohort and published in Chest in 2010. The acronym represents: Hypertension (uncontrolled, SBP > 160 mmHg), Abnormal renal or liver function (1 point each, max 2), prior Stroke history, prior Bleeding or predisposition to bleeding, Labile INR (time in therapeutic range < 60% for warfarin patients), Elderly (age > 65), Drugs (antiplatelet agents or NSAIDs) or alcohol (1 point each, max 2). Total score ranges from 0 to 9. Scores of 0-1 indicate low bleeding risk, 2 is moderate, and ≥3 is high risk. At a score of 3, major bleeding occurs in approximately 3.7 per 100 patient-years; at score ≥4, it rises above 8 per 100 patient-years. The score is widely endorsed by the ESC and incorporated into most AFib management guidelines worldwide as the preferred bleeding risk tool.
• Should I avoid anticoagulation if my HAS-BLED score is high? ▼
  A high HAS-BLED score (≥3) does NOT automatically mean anticoagulation should be withheld. This is one of the most important and commonly misunderstood points in AFib management. The ESC 2024 guidelines explicitly state that a high HAS-BLED score should not be used as a reason to avoid anticoagulation in patients who are otherwise indicated for it based on their CHA₂DS₂-VASc score. Instead, a high HAS-BLED score should trigger active management of modifiable bleeding risk factors and prompt closer follow-up. This is because the absolute risk of a disabling or fatal stroke in high-CHA₂DS₂-VASc patients typically exceeds the absolute risk of a major bleed from anticoagulation. The net clinical benefit calculation consistently favors anticoagulation for most patients with CHA₂DS₂-VASc ≥2 even when HAS-BLED is elevated. When both scores are high, the appropriate response is: control blood pressure, improve INR stability or switch to a DOAC, eliminate NSAIDs, reduce alcohol intake, and then reassess.
• What is the difference between HAS-BLED and other bleeding risk scores like ATRIA and ORBIT? ▼
  Several bleeding risk scores have been developed for AFib patients, each with different variables and derivation cohorts. HAS-BLED uses 9 binary or semi-quantitative variables and produces a 0-9 score; it was derived in a European AFib cohort and has been externally validated in multiple large populations. The ATRIA score (Anticoagulation and Risk Factors in AFib) uses 5 variables including anemia, severe renal disease, age ≥75, prior bleeding, and hypertension with low SBP, with a 0-10 scoring range. The ORBIT score uses 5 variables including reduced hemoglobin or hematocrit, age ≥75, bleeding history, renal impairment, and antiplatelet use. Head-to-head comparisons show generally similar predictive ability across scores, with c-statistics typically in the 0.60-0.70 range. HAS-BLED has the advantage of explicitly identifying modifiable risk factors, making it actionable in clinical practice. The ESC 2024 guidelines continue to endorse HAS-BLED as the preferred bleeding risk tool, while acknowledging that ORBIT and ATRIA are reasonable alternatives.
• How do I lower my HAS-BLED score in practice? ▼
  The value of the HAS-BLED score lies not just in risk prediction but in identifying modifiable risk factors that can be actively addressed to reduce bleeding risk. The four most impactful modifiable components are: (1) Uncontrolled hypertension — achieving consistent SBP < 140 mmHg removes this point and reduces overall cardiovascular risk; (2) Labile INR if on warfarin — consider switching to a DOAC (which eliminates INR variability entirely) or optimizing warfarin dosing to achieve TTR > 70%; (3) Concurrent antiplatelet or NSAID use — review whether aspirin or NSAIDs are truly necessary alongside anticoagulation; aspirin-anticoagulant combination significantly increases bleeding risk with minimal additional stroke prevention; (4) Alcohol excess — reducing to fewer than 8 drinks per week removes this risk factor. Non-modifiable factors (age > 65, prior stroke, prior bleeding history, established renal or liver disease) cannot be changed, but addressing modifiable components can meaningfully shift a patient from high-risk (≥3) to moderate-risk (2) category, improving the net clinical benefit profile of anticoagulation.
• When should HAS-BLED be reassessed in an AFib patient? ▼
  HAS-BLED is not a one-time static score — it should be reassessed at regular intervals and whenever a patient's clinical status changes. The ESC 2024 guidelines recommend reassessing both CHA₂DS₂-VASc and HAS-BLED at every clinical review, typically every 4-6 months, to capture changes in modifiable risk factors. Key triggers for reassessment include: initiation or discontinuation of NSAIDs or antiplatelet agents, changes in renal or liver function (which affect both bleeding risk and DOAC dosing), significant changes in alcohol use, new bleeding events (which add a point), change in blood pressure control, starting or stopping warfarin, and age progression beyond 65 (which adds a point). For patients on warfarin, TTR should be checked regularly; if consistently < 60%, switching to a DOAC can remove the labile INR point and improve both safety and efficacy. Dynamic re-scoring ensures that treatment decisions remain aligned with current patient risk, rather than being based on an outdated one-time assessment.

Related Calculators